GlassScriptPhysician profile
Kashif Naseem
NPI 1699762054
$2,616.11
in general payments reported to CMS, 2019-2025
34 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $280 · 2021: $601 · 2022: $408 · 2023: $468 · 2024: $470 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $581.10 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $211.39 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $174.45 | 2020-2021 | |
| Lilly USA, LLC | $174.37 | 2020-2025 | Mounjaro, Amyvid |
| Novartis Pharmaceuticals Corporation | $146.41 | 2021-2023 | |
| Abbvie INC. | $134.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $102.12 | 2020-2025 | Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.60 | 2019-2021 | |
| Exact Sciences Corporation | $90.53 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $88.91 | 2019-2022 | |
| Lundbeck LLC | $84.94 | 2022-2024 | Rexulti |
| Dexcom, INC. | $72.24 | 2021-2025 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $71.07 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $61.33 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $57.22 | 2020-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $44.40 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $39.97 | 2022 | |
| Sumitomo Pharma America, INC. | $39.72 | 2023 | Gemtesa |
| Greenwich Biosciences, INC. | $35.29 | 2021 | |
| Shield Therapeutics INC | $34.44 | 2025 | |
| Sk Life Science, INC. | $34.04 | 2021 | |
| Abbott Laboratories | $27.28 | 2021-2022 | |
| Indivior INC. | $25.88 | 2020 | |
| Scilex Pharmaceuticals INC. | $22.89 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.00 | 2022 | |
| Eisai INC. | $19.44 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.97 | 2020 | |
| Mylan Specialty L.P. | $16.33 | 2019 | |
| Urovant Sciences INC | $15.29 | 2022 | |
| Merck Sharp & Dohme LLC | $15.03 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2019 | |
| Medtronic Vascular, INC. | $14.75 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.55 | 2022 | |
| Amgen INC. | $13.40 | 2024 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kashif Naseem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.